BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 26889408)

  • 1. The effect of intravenous ascorbic acid in hemodialysis patients with normoferritinemic anemia.
    Kang DW; Ahn CY; Ryu BK; Shin BC; Chung JH; Kim HL
    Kidney Res Clin Pract; 2012 Mar; 31(1):48-53. PubMed ID: 26889408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with hyperferritinemia.
    Tarng DC; Wei YH; Huang TP; Kuo BI; Yang WC
    Kidney Int; 1999 Jun; 55(6):2477-86. PubMed ID: 10354297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous ascorbic acid in hemodialysis patients with functional iron deficiency: a clinical trial.
    Giancaspro V; Nuzziello M; Pallotta G; Sacchetti A; Petrarulo F
    J Nephrol; 2000; 13(6):444-9. PubMed ID: 11132761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low dose intravenous ascorbic acid for erythropoietin-hyporesponsive anemia in diabetic hemodialysis patients with iron overload.
    Lin CL; Hsu PY; Yang HY; Huang CC
    Ren Fail; 2003 May; 25(3):445-53. PubMed ID: 12803508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of intravenous ascorbic acid medication on serum levels of soluble transferrin receptor in hemodialysis patients.
    Tarng DC; Hung SC; Huang TP
    J Am Soc Nephrol; 2004 Sep; 15(9):2486-93. PubMed ID: 15339999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of intravenous ascorbic acid on erythropoiesis and quality of life in unselected hemodialysis patients.
    Taji Y; Morimoto T; Okada K; Fukuhara S; Fukui T; Kuwahara T
    J Nephrol; 2004; 17(4):537-43. PubMed ID: 15372416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
    Attallah N; Osman-Malik Y; Frinak S; Besarab A
    Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous ascorbic acid administration for erythropoietin-hyporesponsive anemia in iron loaded hemodialysis patients.
    Sezer S; Ozdemir FN; Yakupoglu U; Arat Z; Turan M; Haberal M
    Artif Organs; 2002 Apr; 26(4):366-70. PubMed ID: 11952508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A parallel, comparative study of intravenous iron versus intravenous ascorbic acid for erythropoietin-hyporesponsive anaemia in haemodialysis patients with iron overload.
    Tarng DC; Huang TP
    Nephrol Dial Transplant; 1998 Nov; 13(11):2867-72. PubMed ID: 9829492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of short-term intravenous ascorbic acid on reducing ferritin in hemodialysis patients.
    Jalalzadeh M; Shekari E; Mirzamohammadi F; Ghadiani MH
    Indian J Nephrol; 2012 May; 22(3):168-73. PubMed ID: 23087549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Assessment of iron requirements during treatment of anemia with recombinant human erythropoietin in patients with chronic renal insufficiency under hemodialysis].
    Oliveira C; Boquinhas H; Gaspar A; Adragão T; Boquinhas JM; Júnior EC; Simões J
    Acta Med Port; 1992 Jul; 5(7):351-7. PubMed ID: 1442178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative study of intravenous iron versus intravenous ascorbic Acid for treatment of functional iron deficiency in patients under hemodialysis: a randomized clinical trial.
    Sedighi O; Makhlough A; Janbabai G; Neemi M
    Nephrourol Mon; 2013 Sep; 5(4):913-7. PubMed ID: 24350091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of Hepcidin-25 by Short- and Long-Acting rhEPO May Be Dependent on Ferritin and Predict the Response to rhEPO in Hemodialysis Patients.
    Takasawa K; Tomosugi N; Takaeda C; Maeda T; Ueda N
    Nephron Extra; 2014 Jan; 4(1):55-63. PubMed ID: 24847351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Iron replacement in hemodialysis patients with a normal serum ferritin level].
    Riedel MK; Morgenstern T
    Dtsch Med Wochenschr; 2004 Sep; 129(36):1849-53. PubMed ID: 15368155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral vitamin C supplementation reduces erythropoietin requirement in hemodialysis patients with functional iron deficiency.
    Sultana T; DeVita MV; Michelis MF
    Int Urol Nephrol; 2016 Sep; 48(9):1519-24. PubMed ID: 27170339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Intravenous iron sucrose in maintenance dialysis patients with renal anemia: a clinical study].
    Li H; Wang SX
    Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(7):457-62. PubMed ID: 19567093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble transferrin receptors and reticulocyte hemoglobin concentration in the assessment of iron deficiency in hemodialysis patients.
    Fusaro M; Munaretto G; Spinello M; Rebeschini M; Amici G; Gallieni M; Piccoli A
    J Nephrol; 2005; 18(1):72-9. PubMed ID: 15772926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study.
    Coyne DW; Kapoian T; Suki W; Singh AK; Moran JE; Dahl NV; Rizkala AR;
    J Am Soc Nephrol; 2007 Mar; 18(3):975-84. PubMed ID: 17267740
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.